Search

everythinglearnresearchcommunity

for

Search:↓

Using Janus kinase inhibitors (JAKi) in COVID-19 treatment requires careful consideration due to their immunosuppressive effects.

Baricitinib combined with other immune therapies may safely and effectively treat severe scalp hair loss.

China approved Sinovac's flu vaccine, Japan approved RiUP for female hair loss, and Nippon Kayaku's three cancer drugs.

Baricitinib treatment helped reduce hair loss symptoms in mice by decreasing inflammation-related immune cells.

Research on HIV-1 capsid inhibitors has progressed significantly, with the U.S. leading in contributions.

Brepocitinib improves cicatricial alopecia and reduces key immune markers.

Upadacitinib effectively treats psoriasis and lichen planus together.

BBR-SA nanomedicine is a safe and effective treatment for breast cancer.

A man developed skin issues from cancer medication, which improved with specific treatments.

A new compound shows promise as a topical treatment for hair loss.

Drug repurposing offers promising strategies to improve tuberculosis treatment despite challenges.

Upadacitinib can cause hypersensitivity that worsens ulcerative colitis symptoms.

Baricitinib treatment can help regrow scalp hair and eyebrows or eyelashes in people with severe alopecia areata.

Hexahydrobenzo[f]quinolines are effective at blocking the enzyme 5α-reductase.

Baricitinib is effective and safe for long-term use in severe alopecia areata, improving hair regrowth and quality of life with few side effects.

Tofacitinib may help treat hair loss in children with alopecia areata.

A combination of ixekizumab and tofacitinib successfully treated severe scalp cellulitis, leading to hair regrowth.

Ethanamizuril is safe for rats at 20 mg/kg feed, but higher doses cause hair loss, organ changes, and liver, kidney, and lung damage.

Topical patidegib gel effectively treats basal cell carcinoma in Gorlin syndrome patients without causing the side effects seen with oral treatments.

SCD-153 shows promise as an effective topical treatment for alopecia areata.

Hair follicle samples effectively show how well the drug MK-0752 targets and engages with the Notch pathway.

Repurposing existing drugs and using micronutrients may effectively target cancer stem cells and improve cancer treatment.

Diphencyprone (DCP) is an effective treatment for severe alopecia areata and resistant warts, with some risks.

Mange in guinea pigs can be cured with gamma benzene hexachloride washes.

Tofacitinib can cause skin eruptions similar to palmoplantar pustulosis.

Vemurafenib causes significant skin side effects, requiring regular dermatologist care and sun protection.

Some tuberculosis drugs may cause hair loss, but hair might regrow after treatment or changing the drugs.

Secukinumab treatment may cause HBV reactivation and hair discoloration.

No treatment fully prevents hair loss from chemotherapy yet.

A JAK inhibitor improved both severe hair loss and chronic skin disease in one patient.